High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
610.31M
-4.19%
0.013
-117.89%
693.74M
-4.59%
0.697
-18.05%
719.39M
+1.64%
0.970
+53.9%
Estimates Revision
The market is revising Upward the revenue expectations for QuidelOrtho Corporation (QDEL) for FY2025, with the revenue forecasts being adjusted by 0.34% over the past three months. During the same period, the stock price has changed by 4.19%.
Revenue Estimates for FY2025
Revise Upward
+0.34%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.43%
In Past 3 Month
Stock Price
Go Up
+4.19%
In Past 3 Month
7 Analyst Rating
0Wall Street analysts forecast QDEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is 45.00 USD with a low forecast of 27.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
1 Sell
Moderate Buy
0Current: 25.590
Low
27.00
Averages
45.00
High
60.00
0Current: 25.590
Low
27.00
Averages
45.00
High
60.00
Nephron Research
Buy -> Hold
downgrade
$40
2025-07-09
Reason
Nephron Research
Price Target
$40
2025-07-09
downgrade
Buy -> Hold
Reason
Nephron Research downgraded QuidelOrtho to Hold from Buy with a $40 price target.
UBS
Neutral
downgrade
$45 -> $29
2025-05-08
Reason
UBS
Price Target
$45 -> $29
2025-05-08
downgrade
Neutral
Reason
UBS lowered the firm's price target on QuidelOrtho to $29 from $45 and keeps a Neutral rating on the shares. Margins are on track and guidance was reaffirmed amid a smaller-than-expected impact from tariffs, the analyst tells investors in a research note.
Jefferies
Tycho Peterson
Hold
to
Buy
upgrade
$44
2025-05-08
Reason
Jefferies
Tycho Peterson
Price Target
$44
2025-05-08
upgrade
Hold
to
Buy
Reason
Jefferies analyst Tycho Peterson upgraded QuidelOrtho to Buy from Hold with a $44 price target.
Jefferies
Hold
to
Buy
upgrade
$44
2025-05-08
Reason
Jefferies
Price Target
$44
2025-05-08
upgrade
Hold
to
Buy
Reason
JP Morgan
Casey Woodring
Sell
Maintains
$38 → $25
2025-04-21
Reason
JP Morgan
Casey Woodring
Price Target
$38 → $25
2025-04-21
Maintains
Sell
Reason
UBS
John Sourbeer
Hold
Maintains
$43 → $45
2025-02-13
Reason
UBS
John Sourbeer
Price Target
$43 → $45
2025-02-13
Maintains
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for QuidelOrtho Corp (QDEL.O) is 10.77, compared to its 5-year average forward P/E of 15.61. For a more detailed relative valuation and DCF analysis to assess QuidelOrtho Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
15.61
Current PE
10.77
Overvalued PE
21.98
Undervalued PE
9.24
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
8.27
Current EV/EBITDA
7.34
Overvalued EV/EBITDA
10.89
Undervalued EV/EBITDA
5.65
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
2.46
Current PS
0.69
Overvalued PS
4.17
Undervalued PS
0.75
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 9373.92% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 9373.92% over the last month.
Sold
Bought
QDEL News & Events
Events Timeline
(ET)
2025-07-14
07:09:01
QuidelOrtho, BundefinedHLMANN Laboratories announce availability of turbo assays
2025-06-03 (ET)
2025-06-03
16:12:56
QuidelOrtho maintains FY25 guidance issued on February 12
2025-06-03
16:12:18
QuidelOrtho announces a refocusing of its molecular diagnostics strategy
Sign Up For More Events
Sign Up For More Events
News
Preview
1.0
07-17PRnewswireReal Labs, Actual Decisions With Actionable Six Sigma Metrics
Preview
5.0
07-14PRnewswireQUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)
Preview
5.0
07-07NewsfilterQuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs
Sign Up For More News
People Also Watch
FAQ
What is QuidelOrtho Corp (QDEL) stock price today?
What is QuidelOrtho Corp (QDEL)'s business?
What is the price predicton of QDEL Stock?
What is QuidelOrtho Corp (QDEL)'s revenue for the last quarter?
What is QuidelOrtho Corp (QDEL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for QuidelOrtho Corp (QDEL)'s fundamentals?
How many employees does QuidelOrtho Corp (QDEL). have?